Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	Heart rate in b.p.m. (mean (±SD) difference from baseline) at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the response to ivabradine on heart rate after 14 days of stable therapy
Secondary	Heart rate in b.p.m. (mean (±SD) difference from baseline) at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the response to ivabradine on heart rate after 16 weeks of follow-up
Secondary	Serum NT-proBNP in pg/mL (mean (±SD) difference from baseline) at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the response to ivabradine on serum NT-proBNP levels after 14 days of stable therapy
Secondary	Serum NT-proBNP in pg/mL (mean (±SD) difference from baseline) at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the response to ivabradine on serum NT-proBNP levels after 16 weeks of follow-up
Secondary	Correlation between heart rate and NT-proBNP value (Pearson correlation) at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the correlation between heart rate and serum NT-proBNP levels after 14 days of stable therapy
Secondary	Correlation between heart rate and NT-proBNP value (Pearson correlation) at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the correlation between heart rate and serum NT-proBNP levels after 16 weeks of follow-up
Secondary	Left ventricular function, calculated by 2D echocardiographic technique (calculation of left ventricular volume and ejection fraction - mean (±SD) difference from baseline) at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess EF, Left Ventricular End Diastolic Volume (LVEDV), Left Ventricular End Systolic Volume (LVESV) after 14 days of stable therapy
Secondary	Left ventricular function, calculated by 2D echocardiographic technique (calculation of left ventricular volume and ejection fraction - mean (±SD) difference from baseline) at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess EF, LVSV, LVDV after 16 weeks of follow-up
Secondary	Systolic blood pressure in mmHg (mean (±SD) difference from baseline) at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the response to ivabradine on systolic blood pressure after 14 days of stable therapy
Secondary	Systolic blood pressure in mmHg (mean (±SD) difference from baseline) at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the response to ivabradine on systolic blood pressure after 16 weeks of follow-up
Secondary	Use of inotropic drugs (number and % of patients who had to use inotropes at the end of maintenance)	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the need to resort to inotropic drugs within 14 days of stable ivabradine therapy
Secondary	Use of inotropic drugs (number and % of patients who had to use inotropes at the end of follow-up)	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the need to resort to inotropic drugs within 16 weeks of follow-up
Secondary	Number and % of dropouts at the end of maintenance	At the end of the two weeks maintenance period (17-29 days from enrollment)	To assess the frequency of patients who exit from the study within 14 days of stable ivabradine therapy
Secondary	Number and % of dropouts at the end of follow-up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the frequency of patients who exit from the study within 16 weeks of follow-up
Secondary	Time (days) from start of ivabradine therapy and new episode of acute heart failure, and/or implantation of mechanical assist device at the end of follow up	At the end of the 16 weeks follow-up period (129-141 days from enrollment)	To assess the period within main cardiological events would occur after the start of ivabradine therapy

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04405804/registered

API reference For AI assistants